Exelixis soars on blockbuster first-line nod for kidney cancer drug Cabometyx

20th December 2017 Uncategorised 0

When the FDA granted Cabometyx an unexpectedly early approval to treat a bigger group of kidney cancer patients Tuesday, Exelixis shares soared 5% to $28.06. And no wonder—the new first-line approval is expected to push Cabometyx past the $1 billion sales threshold.

More: Exelixis soars on blockbuster first-line nod for kidney cancer drug Cabometyx
Source: fierce